Cargando…

Impact of adult growth hormone deficiency on daily functioning and well-being

BACKGROUND: Adult Growth Hormone Deficiency (AGHD) is a debilitating condition resulting from tumors, pituitary surgery, radiation of the head, head injury, or hypothalamic-pituitary disease. This qualitative study was conducted to better understand the multi-faceted impacts and treatment effects of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brod, Meryl, Pohlman, Betsy, Højbjerre, Lise, Adalsteinsson, Johan Erpur, Rasmussen, Michael Højby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255661/ https://www.ncbi.nlm.nih.gov/pubmed/25406443 http://dx.doi.org/10.1186/1756-0500-7-813

Ejemplares similares

Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)
por: Brod, Meryl, et al.
Publicado: (2018)

Understanding burden of illness for child growth hormone deficiency
por: Brod, Meryl, et al.
Publicado: (2017)

Understanding Treatment Burden for Children Treated for Growth Hormone Deficiency
por: Brod, Meryl, et al.
Publicado: (2017)

Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being
por: Brod, Meryl, et al.
Publicado: (2012)

SUN-248 Growth Hormone Deficiency (GHD): Assessing Burden of Treatment in Children and Adolescents
por: Brod, Meryl, et al.
Publicado: (2019)

Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM)
por: Brod, Meryl, et al.
Publicado: (2021)

Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)
por: Brod, Meryl, et al.
Publicado: (2022)

Letter to the Editor From Sävendahl et al.: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Sävendahl, Lars, et al.
Publicado: (2021)

SAT-091 First Report of Disease-Specific Patient-Reported Outcomes from a Randomized Phase 2 Trial of Once-Weekly Somapacitan vs Daily GH in Children with GHD
por: Brod, Meryl, et al.
Publicado: (2020)

Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once‐weekly somapacitan or daily growth hormone
por: Otsuka, Fumio, et al.
Publicado: (2020)

Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study
por: Brod, Meryl, et al.
Publicado: (2012)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

Assessing physical symptoms, daily functioning, and well‐being in children with achondroplasia
por: Pfeiffer, Kathryn M., et al.
Publicado: (2020)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial
por: Savendahl, Lars S, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin(®) in Children and Adults
por: Papathanasiou, Theodoros, et al.
Publicado: (2021)

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2023)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

Development of the Weight-Related Sign and Symptom Measure
por: Brod, Meryl, et al.
Publicado: (2018)

MON-LB092 Understanding the Patient-Centered Impact of Hypoparathyroidism on Functioning and Well-Being
por: Brod, Meryl, et al.
Publicado: (2019)

Psychometric properties of two measures of psychological well-being in adult growth hormone deficiency
por: McMillan, Carolyn V, et al.
Publicado: (2006)

Benefits of probabilistic sensitivity analysis – a review of NICE decisions
por: Adalsteinsson, Erpur, et al.
Publicado: (2013)

Functioning and well‐being in older children and adolescents with achondroplasia: A qualitative study
por: Pfeiffer, Kathryn M., et al.
Publicado: (2021)

Assessing the impacts of having a child with achondroplasia on parent well-being
por: Pfeiffer, Kathryn M., et al.
Publicado: (2020)

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency
por: Takahashi, Yutaka, et al.
Publicado: (2022)

Correction to: Assessing the impacts of having a child with achondroplasia on parent well-being
por: Pfeiffer, Kathryn M., et al.
Publicado: (2020)

A qualitative study of the impacts of having an infant or young child with achondroplasia on parent well-being
por: Pfeiffer, Kathryn M., et al.
Publicado: (2021)

Understanding compliance issues for daily self-injectable treatment in ambulatory care settings
por: Brod, Meryl, et al.
Publicado: (2008)

Daily Emotional Well-Being and Cardiometabolic Syndrome in Adulthood: The Role of Sleep Deficiency
por: Chai, Hye Won, et al.
Publicado: (2020)

SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension
por: Johannsson, Gudmundur, et al.
Publicado: (2019)

GPS-DERIVED DAILY MOBILITY AND DAILY WELL-BEING IN COMMUNITY-DWELLING OLDER ADULTS
por: Luo, Minxia, et al.
Publicado: (2022)

Normal Sweat Secretion Despite Impaired Growth Hormone-Insulin-Like Growth Factor-I Axis in Obese Subjects
por: Rasmussen, Michael Højby, et al.
Publicado: (2011)

Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in the UK
por: Loftus, Jane, et al.
Publicado: (2022)

RF26 | PMON334 Once-Weekly Somapacitan in Growth Hormone Deficiency: 4-Year Efficacy and Safety Results from REAL 3, a Randomised Controlled Phase 2 Trial
por: Savendahl, Lars, et al.
Publicado: (2022)

SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3)
por: Savendahl, Lars, et al.
Publicado: (2019)

Prosocial Behavior and Contributors to Older Adults’ Well-Being in Daily Life
por: Nakamura, Jeanne, et al.
Publicado: (2020)

Differential effect sizes of growth hormone replacement on quality of life, well-being and health status in growth hormone deficient patients: a meta-analysis
por: Deijen, Jan Berend, et al.
Publicado: (2005)

ODP329 Long-term Effect of Daily Growth Hormone Replacement Therapy on Glucose Tolerance in Adult growth Hormone Deficiency
por: Bando, Hironori, et al.
Publicado: (2022)

STRENGTHS OF GRANDPARENTING: ASSOCIATIONS WITH DAILY WELL-BEING
por: Vo, Tina, et al.
Publicado: (2019)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3detbrnfj7bns5m5tdraa2uikk